Table 2.
Wound closure of monitored test sites during a trial of continuous and biweekly intravenous gentamicin in patients with recessive epidermolysis bullosa
| Location | PT1 | PT2 | PT3 | PT2* | PT3* | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Back | Buttocks | Upper arm | Back | Calf | Shin | Left back |
Lower back | Knee | Calf | |
| Baseline wound area (cm2) | 27.9 | 26.9 | 7.1 | 3.8 | 6.1 | 4.0 | 5.6 | 20.1 | 20.4 | 9.3 |
| Wound history (years)a | > 1 | > 2 | > 1 | > 2 | > 1 | > 1 | > 1 | > 1 | > 1 | > 1 |
| Wound closureb | ||||||||||
| 1 month | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| 3 month | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ |
| 6 month | +++ | +++ | + | + | + | +++ | + | ++ | +++ | +++ |
Patients 1–3 (PT1–PT3) participated in the continuous schedule part of the trial. Later, PT2 and PT3 joined the biweekly schedule part of the trial (denoted as PT2* and PT3*). Percentage of wound closure: 85–100% (+++); 50–85% (++); < 50% (+). PT, patient. aApproximate age of recurrent wounds based on the patients’ recollection. bPercentage of wound closure based on clinical photographs taken at day 0, month 1 and month 3 (see ‘Patients and methods’).